169 related articles for article (PubMed ID: 11286223)
1. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
Hebart H; Brugger W; Grigoleit U; Gscheidle B; Loeffler J; Schäfer H; Kanz L; Einsele H; Sinzger C
Blood; 2001 Apr; 97(7):2183-5. PubMed ID: 11286223
[No Abstract] [Full Text] [Related]
2. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Kiehl MG; Basara N
Blood; 2001 Sep; 98(5):1626; author reply 1628. PubMed ID: 11547768
[No Abstract] [Full Text] [Related]
3. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
4. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
5. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M
Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
[TBL] [Abstract][Full Text] [Related]
7. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
[TBL] [Abstract][Full Text] [Related]
8. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis, treatment, and prophylaxis for cytomegalovirus disease following allogeneic stem cell transplantation].
Gondo H
Rinsho Ketsueki; 2003 Dec; 44(12):1154-60. PubMed ID: 14978931
[No Abstract] [Full Text] [Related]
10. Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
Travi G; Pergam SA; Xie H; Boeckh MJ
Biol Blood Marrow Transplant; 2009 Jun; 15(6):758-60. PubMed ID: 19450762
[No Abstract] [Full Text] [Related]
11. Cytomegalovirus infection following stem cell transplantation.
Einsele H; Hebart H
Haematologica; 1999 Jun; 84 Suppl EHA-4():46-9. PubMed ID: 10907466
[No Abstract] [Full Text] [Related]
12. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
[TBL] [Abstract][Full Text] [Related]
13. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
14. [Infections in bone marrow transplantation].
Villasís-Keever A; Mosqueda JL
Rev Invest Clin; 2005; 57(2):381-6. PubMed ID: 16524081
[No Abstract] [Full Text] [Related]
15. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
Reusser P; Einsele H; Lee J; Volin L; Rovira M; Engelhard D; Finke J; Cordonnier C; Link H; Ljungman P;
Blood; 2002 Feb; 99(4):1159-64. PubMed ID: 11830461
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.
Marchesi F; Pimpinelli F; Ensoli F; Mengarelli A
Hematol Oncol; 2018 Apr; 36(2):381-391. PubMed ID: 28660653
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature.
Baghban A; Malinis M
J Neurol Sci; 2018 May; 388():28-36. PubMed ID: 29627026
[TBL] [Abstract][Full Text] [Related]
20. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
